SciSparc Subsidiary Merger Approved by N2OFF Shareholders
Ticker: SPRC · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, drug-development, oncology
TL;DR
SciSparc subsidiary MitoCareX merger with N2OFF approved, advancing cancer drug pipeline.
AI Summary
SciSparc Ltd. announced on September 29, 2025, that N2OFF shareholders approved a merger with SciSparc's majority-owned subsidiary, MitoCareX. MitoCareX is a drug discovery company focused on resistant cancers, including pancreatic cancer.
Why It Matters
This merger could advance SciSparc's drug development pipeline for difficult-to-treat cancers, potentially leading to new therapeutic options.
Risk Assessment
Risk Level: medium — Mergers and drug development carry inherent risks, including regulatory hurdles and clinical trial outcomes.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- N2OFF (company) — Shareholder entity
- MitoCareX (company) — SciSparc's majority-owned subsidiary
- September 29, 2025 (date) — Announcement date
FAQ
What is the primary focus of MitoCareX?
MitoCareX is a drug discovery company targeting resistant cancers, including pancreatic cancer.
Which entity's shareholders approved the merger?
N2OFF shareholders approved the merger.
What is the relationship between SciSparc and MitoCareX?
MitoCareX is a majority-owned subsidiary of SciSparc.
On what date was this merger approval announced?
The announcement was made on September 29, 2025.
What type of filing is this report?
This is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 336 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-09-30 07:01:56
Filing Documents
- ea0259447-6k_scisparc.htm (6-K) — 13KB
- ea025944701ex99-1_scisparc.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-093386.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: September 30, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3